Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camp4 TherapeuticsCAMP +0.67%8 Current Ratio is 4.70 as of Jun. 2026, which is 24% below its 10-year median of 6.15. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Camp4 Therapeutics ranks better than 55.78% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Camp4 Therapeutics's current ratio for the quarter that ended in Jun. 2026 was 4.70.
Camp4 Therapeutics has a current ratio of 4.70. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Camp4 Therapeutics's Current Ratio or its related term are showing as below:
CAMP'
s Current Ratio Range Over the Past 10 Years
Min: 0.47 Med: 6.15 Max: 10.62
Current: 4.7
During the past 4 years, Camp4 Therapeutics's highest Current Ratio was 10.62. The lowest was 0.47. And the median was 6.15.
CAMP's Current Ratio is ranked better than 55.78% of 1411
companies
in the Biotechnology industry
Industry Median: 3.89
vs CAMP: 4.70
Camp4 Therapeutics (NAS:CAMP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Camp4 Therapeutics Current Ratio Related Terms
Camp4 Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Camp4 Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMP vs ALEC, ORMP, PYXS: Current Ratio Comparison
For the Biotechnology subindustry, Camp4 Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camp4 Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Camp4 Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camp4 Therapeutics (CAMP) has a Current Ratio of 4.70 as of Jun. 2026. This is 24% below median its historical median of 6.15. Over the past decade, Camp4 Therapeutics' Current Ratio has ranged from 0.47 to 10.62. According to the industry distribution chart, Camp4 Therapeutics ranks #624 out of 1411 companies in the Biotechnology industry, placing it in the top 44.2%.
Is Camp4 Therapeutics' Current Ratio too high?
Camp4 Therapeutics' current Current Ratio of 4.70 is 24% below median its 10-year median of 6.15. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 10.62. The Biotechnology industry median Current Ratio is 3.89. Camp4 Therapeutics' value of 4.70 is 20.8% above this industry median. Based on the distribution chart, Camp4 Therapeutics ranks #624 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Current Ratio compare to ALEC and ORMP?
According to the Biotechnology industry distribution chart, Camp4 Therapeutics ranks #624 out of 1411 companies for Current Ratio. This puts Camp4 Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.89. Camp4 Therapeutics' value of 4.70 is 20.8% above this benchmark. Historically, Camp4 Therapeutics' own Current Ratio has ranged from 0.47 to 10.62 over the past decade. While the company's 10-year median is 6.15 vs. the industry median of 3.89, Camp4 Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camp4 Therapeutics's current Current Ratio of 4.70 is 20.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camp4 Therapeutics's current Current Ratio is 4.70, which is 24% below median its own 10-year median of 6.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Current Ratio of 4.70. The current Current Ratio is 4.70, which is 24% below median its 10-year median of 6.15 and 20.8% above the Biotechnology industry median of 3.89. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Current Ratio is 4.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score
Get the complete analysis for CAMP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMP has been successfully added to your 
